CRISPR Lateral Flow Control Lines: What They Do and Do Not Verify

A visible control line on a CRISPR lateral flow strip is not, by itself, evidence that sample preparation, amplification and the CRISPR reaction all worked. Its meaning depends on the strip architecture and the assay’s validated interpretation rules. Research teams should define which stage each control actually challenges before interpreting a negative target result.

Start with the question each control answers

Control Question to validate Boundary
Strip control feature Did the specified control signal develop under the strip instructions? Does not automatically test upstream nucleic-acid recovery or enzyme activity.
Process control introduced before preparation Can the selected control material pass through the stages it accompanies? Its behaviour must represent the intended sample and workflow.
Internal amplification control Can a defined control sequence amplify in the sample reaction? Control design and competition can affect sensitivity.
Positive reaction control Can the tested reaction and readout produce the expected result? A separate control tube does not establish that another sample is uninhibited.
No-template control Does the run show an unexpected signal without added target template? Does not measure recovery from a real sample.

Why an amplification control is a separate design decision

Hoorfar and colleagues describe internal amplification controls in PCR and explain why a negative target signal can reflect inhibition. Their discussion also highlights competition between control and target amplification. This PCR guidance supports the distinction between control functions; it is not validation of a particular CRISPR, RPA or lateral-flow product. A control transferred to another chemistry needs its own evaluation.

Interpret lines using the selected strip instructions

Do not apply a universal rule that two lines mean positive. Reporter cleavage, capture layout and signal direction depend on the chosen format. Record the strip model, reporter labels, expected patterns for each control and the permitted reading window from the applicable instructions. A visually plausible line pattern cannot replace missing upstream controls.

Separate a component enquiry from assay validation

DueBio JY0301 Cas12/13 strips are readout components for research workflow evaluation, not complete pathogen-specific tests. If sample preparation is also being evaluated, review the relevant BT0068 release reagent documentation separately. Compatibility must be established for the complete reaction and sample matrix.

For evaluation, bulk supply or OEM enquiries, contact DueBio/TiosBio with the strip model, reporter design, sample matrix and the control functions your development team needs to evaluate.

Reference and scope

Hoorfar et al. Practical Considerations in Design of Internal Amplification Controls for Diagnostic PCR Assays. Journal of Clinical Microbiology (2004). DOI: 10.1128/JCM.42.5.1863-1868.2004. This is general research-development guidance, not a validated clinical interpretation algorithm or a new DueBio performance study.

TL
Global Agent · Duebio (TiosBio) · 20+ Years in IVD
IVD industry veteran specializing in CRISPR Cas12/Cas13 detection, RAA isothermal amplification, lateral flow assays, microfluidic PCR, TRF immunoassays, and OEM/ODM IVD development for global distributors. Duebio is the international trade brand of TiosBio, a Chinese IVD manufacturer with 20+ years of experience.

Leave a Comment